ethyl-thiomandelate | 62754-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-thiomandelate
• 英文别名: ethyl 2-phenyl-2-sulfanylacetate；ethyl 2-mercapto-2-phenylacetate；α-Mercapto-phenylessigsaeure-ethylester；mercapto-phenyl-acetic acid ethyl ester；ethyl 2-phenyl-2-mercaptoacetate
• CAS: 62754-88-5
• 化学式: C₁₀H₁₂O₂S
• 分子量: 196.27
• InChiKey: SKZPUJNZLGMHDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl-thiomandelate 在 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 苯 为溶剂， 反应 20.0h， 生成 [(Z)-5-(2-diethylamino-ethyl)-3-methyl-4-oxo-5-phenyl-thiazolidin-2-ylidene]-acetic acid ethyl ester
  参考文献：
  名称：

  Satzinger,G., Justus Liebigs Annalen der Chemie, 1978, p. 473 - 511

  摘要：

  DOI：
• 作为产物：
  描述：

  α-溴苯乙酸乙酯 在 sodium ethanolate 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 1.0h， 生成 ethyl-thiomandelate
  参考文献：
  名称：

  用于非洲锥虫病的 s-三嗪衍生物的体外评价

  摘要：

  DOI：

  10.1002/bkcs.10447

文献信息

• [EN] TETRAHYDROCARBAZOLES AND DERIVATIVES<br/>[FR] TETRAHYDROCARBAZOLES ET DERIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092856A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRß agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在描述和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物对于治疗和预防由LXRα和/或LXRß激动剂调节的疾病是有用的，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇、高LDL-胆固醇、动脉粥样硬化疾病、糖尿病，特别是非胰岛素依赖型糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病如结肠炎、胰腺炎、肝胆瘀积/肝纤维化，以及具有炎症成分的疾病，如阿尔茨海默病或认知功能受损/可改善的疾病。
• Syntheses of 4-(benzo[<i>b</i>]furan-2 or 3-yl)- and 4-(benzo[<i>b</i>]-thiophen-3-yl)piperidines with 5-HT₂antagonist activity
  作者：Yoshifumi Watanabe、Hirotaka Yoshiwara、Munefumi Kanao

  DOI：10.1002/jhet.5570300228

  日期：1993.3

  The syntheses of 4-(benzo[b]furan-3-yl)piperidines, 4-(benzo[b]furan-2-yl)piperidines and 4-(benzo[b]thiophen-3-yl)piperidines with 5-HT2 antagonist activity are described. Reaction of 1-acetyl-4-(2,4-difluorobenzo-yl)piperidine 2 with methyl glycolate gave methyl 6-fluoro-3-(1-acetylpiperidin-4-yl)benzo[b]furan-2-carboxylate 3, which was converted to 2-[2-[4-(benzo[b]furan-3-yi)piperidin-1-yl]ethyl-5

  4-（苯并[ b ]呋喃-3-基）哌啶，4-（苯并[ b ]呋喃-2-基）哌啶和4-（苯并[ b ]噻吩-3-基）哌啶的合成与5-描述了HT 2拮抗剂活性。1-乙酰基-4-（2,4-二氟苯甲酰基）哌啶2与乙醇酸甲酯反应，得到6-氟-3-（1-乙酰基哌啶-4-基）苯并[ b ]呋喃-2-羧酸甲酯3，将其转化为2- [2- [4-（苯并[ b ]呋喃-3-乙氧基]哌啶-1-基]乙基-5,6,7,8-四氢-1,2,4-三唑-[ 4,3-一]吡啶-3（2 H）一盐酸盐9。类似的苯并[ b ]呋喃17a-d苯并[ b ]噻吩10a，b和18a通过类似的方法制备。将4-氟-2-（4-吡啶基甲氧基）苯乙酮环化，得到4-（苯并[ b ]呋喃-2-基）吡啶21a，b，将其转化为2- [2- [4-（苯并] [ b ]呋喃-2-基）-哌啶-1-基]乙基5,6,7,8-四氢-1,2,4-三唑并[4,3- a ]吡啶-3（2
• Antiinflammatory and immunoregulatory pyrimidines, their method of use
  申请人：Pfizer Inc.

  公开号：US04246263A1

  公开（公告）日：1981-01-20

  A series of 4-(2-hydroxyethylthiomethyl)pyridines and related compounds, and their pharmaceutically acceptable acid addition salts, having antiinflammatory and immunoregulatory activity are disclosed. Preferred compounds include 4-(2-hydroxyethylthiomethyl)pyridine itself, as well as 4-(2-hydroxyphenylthiomethyl)pyridine, 4-(2-hydroxy-1-propylthiomethyl)pyridine, 4-(3-hydroxy-2-butylthiomethyl)pyridine, 4-(2-hydroxyethylthiomethyl)pyrimidine, the acetate esters corresponding to the above compounds, and 4-(2,3-dihydroxy-1-propylthiomethyl)pyridine.

  揭示了一系列4-(2-羟乙基硫甲基)吡啶和相关化合物，以及它们的药用可接受的酸盐，具有抗炎和免疫调节活性。首选化合物包括4-(2-羟乙基硫甲基)吡啶本身，以及4-(2-羟基苯硫甲基)吡啶，4-(2-羟基-1-丙基硫甲基)吡啶，4-(3-羟基-2-丁基硫甲基)吡啶，4-(2-羟乙基硫甲基)嘧啶，与上述化合物对应的乙酸酯，以及4-(2,3-二羟基-1-丙基硫甲基)吡啶。
• Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Stapper Christian

  公开号：US20050101637A1

  公开（公告）日：2005-05-12

  Provided herein are novel compounds of formula I below: in which the radicals are as defined, their physiologically acceptable salts, processes for their preparation, as well as methods of treating and/or preventing disorders of disorders of fatty acid metabolism and glucose utilization disorders, and also of disorders in which insulin resistance is involved, in a patient.

  本文提供了以下公式I的新化合物： 其中基团的定义如下，它们的生理学上可接受的盐，其制备过程，以及治疗和/或预防患者体内脂肪酸代谢和葡萄糖利用障碍，以及胰岛素抵抗相关的障碍的方法。
• Tetrahydrocarbazoles and derivatives
  申请人：Dehmlow Henrietta

  公开号：US20050215577A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物在LXRα和/或LXRβ激动剂调节的疾病的治疗和预防中有用，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇，高LDL-胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，脂质代谢异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化和具有炎症成分的疾病，如阿尔茨海默病或受损/可改善的认知功能。